News Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Real-time Estimate Cboe BZX Other stock markets 02:20:04 2024-04-19 pm EDT			5-day change	1st Jan Change
0.784 ^USD	-0.46%		-8.43%	-16.61%

Mar. 14	Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Apr. 08	BU
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update	Mar. 14	BU
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Mar. 08	BU
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 28	BU
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis	Feb. 26	BU
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)	Dec. 04	PR
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	Nov. 21	BU
Wells Fargo Adjusts Price Target on Kezar Life Sciences to $2 From $4, Maintains Equal-Weight Rating	Nov. 14	MT
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	BU
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 09	AQ
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Nov. 03	BU
KEZAR ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)	23-10-10	AQ
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-10	AQ
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	23-10-09	BU
North American Morning Briefing : Investors Await -2-	23-10-06	DJ
JonesTrading Downgrades Kezar Life Sciences to Hold From Buy	23-10-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Summary

Filters